Infiltration of primary melanomas with T lymphocytes is associated with a favorable clinical outcome. This suggests that T cell-based immunotherapies may be beneficial for melanoma patients. However, adoptive cytolytic T lymphocyte (CTL) immunotherapy of melanoma patients and active immunotherapy with CTL-based antigen (Ag)/peptide vaccines have not held promise. These limitations may rest in the selection for immunotherapy of CTL in vitro that do not reflect the Ag specificity of the CTL in situ. CTL traditionally are selected in two-dimensional mixed lymphocyte-tumor culture (MLTC) directly on plastic surfaces. We have developed the three-dimensional human melanoma organolypic culture model (melanoma reconstruct) in which CTL are cultured under tissue-like condition. Our preliminary studies suggest that the T cell receptor (TCR) repertoire in tumor reconstructs more closely resembles the repertoire of the T cells in situ as compared to the TCR repertoire in MLTC. However, the two culture systems are complementary. Thus, the chances of generating T cells with in situ (tissue)-Iike TCR are enhanced when T cells from both culture systems are cornbined, compared to either culture alone. Our major goal is to develop, including the melanoma reconstruct as a culture system, improved CTL-based adoptive and active immunotherapies against melanoma. Specifically we will: 1. Compare the phenotypic (CD markers, TCR, adhesion and apoptosis-related molecules, HLA, chemokines, chemokine receptors) and functional characteristics (proliferative and lytic activity; cytokine production) of CTL derived from fresh tissues in the reconstruct or MLTC. 2. Clone Ag(s) recognized by CTL that are highly cytolytic and express the original TCR found in situ. These Ags have vaccine potential for melanoma patients and may boost pre-existing immune responses. 3. Identify chemokines and chemokine receptors that are involved in CTL migration toward tumor cells in the reconstruct. This involves: i) Selection of migrating CTL and ii) blocking of chemokines and their receptors to determine their role in CTL migration. Chemokines relevant in CTL migration in the reconstruct may be used to enhance anti-tumor effects of adoptive and active immunotherapy. The proposed studies open new approaches to CTL-based adoptive and active immunotherapies, which may be initiated during the third year of the SPORE.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
2P50CA093372-03
Application #
6990749
Study Section
Special Emphasis Panel (ZCA1-GRB-V (O1))
Project Start
2004-07-27
Project End
2009-06-30
Budget Start
2004-07-27
Budget End
2005-06-30
Support Year
3
Fiscal Year
2004
Total Cost
$159,134
Indirect Cost
Name
Wistar Institute
Department
Type
DUNS #
075524595
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Ojha, Rani; Leli, Nektaria M; Onorati, Angelique et al. (2018) ER translocation of the MAPK pathway drives therapy resistance in BRAF mutant melanoma. Cancer Discov :
Kugel 3rd, Curtis H; Douglass, Stephen M; Webster, Marie R et al. (2018) Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations. Clin Cancer Res 24:5347-5356
Nti, Akosua A; Serrano, Leona W; Sandhu, Harpal S et al. (2018) FREQUENT SUBCLINICAL MACULAR CHANGES IN COMBINED BRAF/MEK INHIBITION WITH HIGH-DOSE HYDROXYCHLOROQUINE AS TREATMENT FOR ADVANCED METASTATIC BRAF MUTANT MELANOMA: Preliminary Results From a Phase I/II Clinical Treatment Trial. Retina :
Onorati, Angelique V; Dyczynski, Matheus; Ojha, Rani et al. (2018) Targeting autophagy in cancer. Cancer 124:3307-3318
Noguera-Ortega, Estela; Amaravadi, Ravi K (2018) Autophagy in the Tumor or in the Host: Which Plays a Greater Supportive Role? Cancer Discov 8:266-268
Rebecca, Vito W; Nicastri, Michael C; Fennelly, Colin et al. (2018) PPT1 promotes tumor growth and is the molecular target of chloroquine derivatives in cancer. Cancer Discov :
Garman, Bradley; Anastopoulos, Ioannis N; Krepler, Clemens et al. (2017) Genetic and Genomic Characterization of 462 Melanoma Patient-Derived Xenografts, Tumor Biopsies, and Cell Lines. Cell Rep 21:1936-1952
Rebecca, Vito W; Nicastri, Michael C; McLaughlin, Noel et al. (2017) A Unified Approach to Targeting the Lysosome's Degradative and Growth Signaling Roles. Cancer Discov 7:1266-1283
Ndoye, Abibatou; Budina-Kolomets, Anna; Kugel 3rd, Curtis H et al. (2017) ATG5 Mediates a Positive Feedback Loop between Wnt Signaling and Autophagy in Melanoma. Cancer Res 77:5873-5885
Taylor, Laura A; Abraham, Ronnie M; Tahirovic, Emin et al. (2017) High ALDH1 expression correlates with better prognosis in tumorigenic malignant melanoma. Mod Pathol 30:634-639

Showing the most recent 10 out of 106 publications